Cargando…
Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies. However, cu...
Autores principales: | Chanprapaph, K., Vachiramon, V., Rattanakaemakorn, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958662/ https://www.ncbi.nlm.nih.gov/pubmed/24723942 http://dx.doi.org/10.1155/2014/734249 |
Ejemplares similares
-
The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
por: Owczarek, Witold, et al.
Publicado: (2017) -
Cutaneous adverse reactions specific to epidermal growth
factor receptor inhibitors
por: Lupu, I, et al.
Publicado: (2015) -
Cutaneous Mycobacterium abscessus Infection Associated with Mesotherapy Injection
por: Wongkitisophon, Pranee, et al.
Publicado: (2011) -
Cutaneous nontuberculous mycobacterial infection in Thailand: A 7-year retrospective review
por: Chirasuthat, Phatcharawat, et al.
Publicado: (2020) -
Outcome of Repeated Use of Donor Site for Noncultured Epidermal Cellular Grafting in Stable Vitiligo: A Retrospective Study
por: Vachiramon, Vasanop, et al.
Publicado: (2019)